title: Bone mineral density and body composition in Noonan's syndrome: effects of growth hormone treatment.
abstract: We assessed bone mineral density (BMD) and body composition in children with Noonan's syndrome (NS) before and during growth hormone (GH) treatment. Sixteen children (12 boys, 4 girls) with NS aged 5.8-14.2 (mean 10.0) years were studied for 2 years. Anthropometry, BMD measurements by radiographic absorptiometry and bioimpedance measurements (Akern-BIA 101/S) were performed at baseline and after 3, 6, 12 and 24 months. Daily GH dosage was 0.05 mg/kg. Trabecular volumetric BMD was normal; cortical BMD was in the lower normal range at baseline and slightly increased over the 2 years. Fat free mass and total body water were below normal at the start and increased significantly over the first 3 months, with a slight increment thereafter. Percentage fat mass decreased over the first 6 months and increased thereafter. These findings are comparable to the data on body composition in short normal children and girls with Turner's syndrome treated with GH.
authors.affiliation: Department of Paediatric Endocrinology, University Medical Centre St. Radboud, Nijmegen, The Netherlands. C.Noordam@ckskg.azn.nl
authors.forename: C
authors.initials: C
authors.lastname: Noordam
authors.forename: J
authors.initials: J
authors.lastname: Span
authors.forename: R R
authors.initials: RR
authors.lastname: van Rijn
authors.forename: E
authors.initials: E
authors.lastname: Gomes-Jardin
authors.forename: C
authors.initials: C
authors.lastname: van Kuijk
authors.forename: B J
authors.initials: BJ
authors.lastname: Otten
mesh_terms: D015502:Absorptiometry, Photon; D000273:Adipose Tissue / Q000473:pathology; D000293:Adolescent; D015415:Biomarkers; D001823:Body Composition / Q000187:drug effects / Q000502:physiology*; D015519:Bone Density / Q000187:drug effects / Q000502:physiology*; D002648:Child; D017097:Electric Impedance; D005260:Female; D013006:Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009634:Noonan Syndrome / Q000188:drug therapy* / Q000473:pathology*
chemical_list: D015415:Biomarkers; D013006:Growth Hormone